Achieve Life Sciences (ACHV) Competitors

$4.77 -0.52 (-9.83%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$4.84 +0.07 (+1.36%)

As of 05/18/2026 07:36 PM Eastern

ACHV vs. MNKD, GERN, LXRX, OPK, and IRWD

Should you buy Achieve Life Sciences stock or one of its competitors? MarketBeat compares Achieve Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Achieve Life Sciences include MannKind (MNKD), Geron (GERN), Lexicon Pharmaceuticals (LXRX), OPKO Health (OPK), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry.

How does Achieve Life Sciences compare to MannKind?

Achieve Life Sciences (NASDAQ:ACHV) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

In the previous week, Achieve Life Sciences had 14 more articles in the media than MannKind. MarketBeat recorded 26 mentions for Achieve Life Sciences and 12 mentions for MannKind. MannKind's average media sentiment score of 0.88 beat Achieve Life Sciences' score of 0.69 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Achieve Life Sciences has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-193.49%	-111.88%
MannKind	-6.63%	-11.21%	-3.92%

Achieve Life Sciences presently has a consensus target price of $14.67, suggesting a potential upside of 207.48%. MannKind has a consensus target price of $8.84, suggesting a potential upside of 195.78%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Achieve Life Sciences is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

MannKind has higher revenue and earnings than Achieve Life Sciences. MannKind is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A
MannKind	$348.97M	2.65	$5.86M	-$0.07	N/A

Achieve Life Sciences has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market. Comparatively, MannKind has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 3.0% of Achieve Life Sciences shares are held by company insiders. Comparatively, 2.6% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Achieve Life Sciences and MannKind tied by winning 8 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to Geron?

Achieve Life Sciences (NASDAQ:ACHV) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Achieve Life Sciences has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A
Geron	$183.88M	4.29	-$83.50M	-$0.11	N/A

In the previous week, Achieve Life Sciences had 22 more articles in the media than Geron. MarketBeat recorded 26 mentions for Achieve Life Sciences and 4 mentions for Geron. Geron's average media sentiment score of 0.86 beat Achieve Life Sciences' score of 0.69 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 3.0% of Achieve Life Sciences shares are owned by company insiders. Comparatively, 1.7% of Geron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Achieve Life Sciences has a net margin of 0.00% compared to Geron's net margin of -35.48%. Geron's return on equity of -23.31% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-193.49%	-111.88%
Geron	-35.48%	-23.31%	-10.08%

Achieve Life Sciences presently has a consensus target price of $14.67, indicating a potential upside of 207.48%. Geron has a consensus target price of $2.50, indicating a potential upside of 103.25%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Achieve Life Sciences has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market. Comparatively, Geron has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Summary

Achieve Life Sciences beats Geron on 10 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to Lexicon Pharmaceuticals?

Achieve Life Sciences (NASDAQ:ACHV) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Achieve Life Sciences currently has a consensus price target of $14.67, suggesting a potential upside of 207.48%. Lexicon Pharmaceuticals has a consensus price target of $4.55, suggesting a potential upside of 112.62%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Achieve Life Sciences has a beta of 2.25, suggesting that its stock price is 125% more volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Lexicon Pharmaceuticals has higher revenue and earnings than Achieve Life Sciences. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A
Lexicon Pharmaceuticals	$69.64M	13.65	-$50.34M	-$0.07	N/A

In the previous week, Achieve Life Sciences had 16 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 26 mentions for Achieve Life Sciences and 10 mentions for Lexicon Pharmaceuticals. Achieve Life Sciences' average media sentiment score of 0.69 beat Lexicon Pharmaceuticals' score of 0.51 indicating that Achieve Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Achieve Life Sciences has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-193.49%	-111.88%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 3.0% of Achieve Life Sciences shares are held by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Achieve Life Sciences beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to OPKO Health?

OPKO Health (NASDAQ:OPK) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

In the previous week, Achieve Life Sciences had 21 more articles in the media than OPKO Health. MarketBeat recorded 26 mentions for Achieve Life Sciences and 5 mentions for OPKO Health. Achieve Life Sciences' average media sentiment score of 0.69 beat OPKO Health's score of 0.61 indicating that Achieve Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Achieve Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 49.7% of OPKO Health shares are owned by company insiders. Comparatively, 3.0% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Achieve Life Sciences has a net margin of 0.00% compared to OPKO Health's net margin of -36.63%. OPKO Health's return on equity of -16.78% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Achieve Life Sciences	N/A	-193.49%	-111.88%

OPKO Health has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market.

Achieve Life Sciences has lower revenue, but higher earnings than OPKO Health. Achieve Life Sciences is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.41	-$225.68M	-$0.27	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A

OPKO Health currently has a consensus price target of $1.55, indicating a potential upside of 37.17%. Achieve Life Sciences has a consensus price target of $14.67, indicating a potential upside of 207.48%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Achieve Life Sciences beats OPKO Health on 9 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to Ironwood Pharmaceuticals?

Achieve Life Sciences (NASDAQ:ACHV) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

In the previous week, Achieve Life Sciences had 21 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 26 mentions for Achieve Life Sciences and 5 mentions for Ironwood Pharmaceuticals. Achieve Life Sciences' average media sentiment score of 0.69 beat Ironwood Pharmaceuticals' score of 0.48 indicating that Achieve Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ironwood Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Achieve Life Sciences presently has a consensus price target of $14.67, indicating a potential upside of 207.48%. Ironwood Pharmaceuticals has a consensus price target of $6.23, indicating a potential upside of 78.10%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Achieve Life Sciences is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Achieve Life Sciences has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Ironwood Pharmaceuticals has a net margin of 28.26% compared to Achieve Life Sciences' net margin of 0.00%. Ironwood Pharmaceuticals' return on equity of -39.65% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-193.49%	-111.88%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

33.5% of Achieve Life Sciences shares are held by institutional investors. 3.0% of Achieve Life Sciences shares are held by company insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ironwood Pharmaceuticals has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A
Ironwood Pharmaceuticals	$296.15M	1.93	$24.02M	$0.60	5.83

Summary

Achieve Life Sciences and Ironwood Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Achieve Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACHV vs. The Competition

Export

Metric	Achieve Life Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$281.61M	$3.00B	$6.25B	$12.29B
Dividend Yield	N/A	1.98%	2.80%	5.30%
P/E Ratio	-4.26	17.22	20.86	25.23
Price / Sales	N/A	275.32	549.93	74.46
Price / Cash	N/A	56.35	27.48	37.30
Price / Book	11.93	3.93	9.67	6.63
Net Income	-$54.65M	$74.99M	$3.56B	$335.59M
7 Day Performance	-20.37%	-4.47%	-1.70%	-1.20%
1 Month Performance	-6.47%	-7.93%	-2.66%	-1.16%
1 Year Performance	44.11%	29.34%	30.03%	28.10%

Achieve Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACHV Achieve Life Sciences	2.8417 of 5 stars	$4.77 -9.8%	$14.67 +207.5%	+54.9%	$281.61M	N/A	N/A	20	Earnings Report Analyst Upgrade Analyst Revision Gap Up
MNKD MannKind	3.9734 of 5 stars	$3.36 -4.5%	$8.84 +163.2%	-31.6%	$1.09B	$348.97M	N/A	400	Analyst Revision
GERN Geron	2.4322 of 5 stars	$1.39 flat	$2.50 +79.9%	-3.1%	$891.71M	$183.88M	N/A	70	High Trading Volume
LXRX Lexicon Pharmaceuticals	2.5899 of 5 stars	$2.31 +15.5%	$4.55 +97.0%	+299.9%	$888.39M	$49.80M	N/A	140	High Trading Volume
OPK OPKO Health	2.7655 of 5 stars	$1.12 -1.8%	$1.55 +38.4%	-15.0%	$860.80M	$606.90M	N/A	1,373	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACHV) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Achieve Life Sciences (ACHV) Competitors

ACHV vs. MNKD, GERN, LXRX, OPK, and IRWD

How does Achieve Life Sciences compare to MannKind?

Summary

How does Achieve Life Sciences compare to Geron?

Summary

How does Achieve Life Sciences compare to Lexicon Pharmaceuticals?

Summary

How does Achieve Life Sciences compare to OPKO Health?

Summary

How does Achieve Life Sciences compare to Ironwood Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV vs. The Competition

Achieve Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Achieve Life Sciences (ACHV) Competitors

ACHV vs. MNKD, GERN, LXRX, OPK, and IRWD

How does Achieve Life Sciences compare to MannKind?

Does the media favor ACHV or MNKD?

Is ACHV or MNKD more profitable?

Do analysts rate ACHV or MNKD?

Which has stronger earnings & valuation, ACHV or MNKD?

Which has more volatility and risk, ACHV or MNKD?

Do insiders and institutionals have more ownership in ACHV or MNKD?

Summary

How does Achieve Life Sciences compare to Geron?

Which has preferable earnings & valuation, ACHV or GERN?

Does the media favor ACHV or GERN?

Do insiders & institutionals believe in ACHV or GERN?

Is ACHV or GERN more profitable?

Do analysts prefer ACHV or GERN?

Which has more risk and volatility, ACHV or GERN?

Summary

How does Achieve Life Sciences compare to Lexicon Pharmaceuticals?

Do analysts recommend ACHV or LXRX?

Which has more risk and volatility, ACHV or LXRX?

Which has preferable valuation and earnings, ACHV or LXRX?

Does the media prefer ACHV or LXRX?

Is ACHV or LXRX more profitable?

Do insiders and institutionals hold more shares of ACHV or LXRX?

Summary

How does Achieve Life Sciences compare to OPKO Health?

Does the media favor OPK or ACHV?

Do institutionals and insiders believe in OPK or ACHV?

Is OPK or ACHV more profitable?

Which has more risk and volatility, OPK or ACHV?

Which has higher valuation and earnings, OPK or ACHV?

Do analysts prefer OPK or ACHV?

Summary

How does Achieve Life Sciences compare to Ironwood Pharmaceuticals?

Does the media prefer ACHV or IRWD?

Do analysts recommend ACHV or IRWD?

Which has more volatility and risk, ACHV or IRWD?

Is ACHV or IRWD more profitable?

Do insiders & institutionals believe in ACHV or IRWD?

Which has better earnings & valuation, ACHV or IRWD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV vs. The Competition

Achieve Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools